Symptom relief with LACRISERT ®

LACRISERT® acts like a slow-release, preservative-free artificial tear1,2

  • Prolongs the tear film breakup time
  • Provides ocular surface protection
  • Provided greater reduction of moderate to severe dry eye syndrome symptoms and signs than artificial tears
  • Stabilizes and thickens the precorneal tear film

LACRISERT® reduced the key symptoms of dry eye

Reduction in symptoms based on a multicenter, prospective, open-label patient registry (N=520)3

LACRISERT® can be used as adjunctive therapy for greater symptom reduction

53%
of patients felt that LACRISERT® improved the effectiveness of their existing therapy3,
Included artificial tears, punctal plugs, and cyclosporine emulsion.

Most patients remain on LACRISERT®

76%
of patients who received LACRISERT® remained on therapy 1 year later in a retrospective case study (n=80)1

Indications and Usage

LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT® is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT® is also indicated for patients with exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.

Important Safety Information

  • LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose.
  • Instructions for inserting and removing LACRISERT® should be carefully followed.
  • If improperly placed, LACRISERT® may result in corneal abrasion. Because LACRISERT® may cause transient blurred vision, patients should be instructed to exercise caution when driving or operating machinery.
  • The following adverse reactions have been reported, but were in most instances mild and temporary: transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, eyelid edema, and hyperemia.

Click here for full Prescribing Information

References: 1. Wander AH, Koffler BH. Extending the duration of tear film protection in dry eye syndrome: review and retrospective case series study of the hydroxypropyl cellulose ophthalmic insert. Ocul Surf. 2009;7(3):154-162. 2. LACRISERT [package insert]. Bridgewater, NJ: Bausch & Lomb. 3. Koffler BH, McDonald M, Nelinson DS; for LAC-07-01 Study Group. Improved signs, symptoms, and quality of life associated with dry eye syndrome: hydroxypropyl cellulose ophthalmic insert patient registry. Eye Contact Lens. 2010;36(3):170-176.

Indications and Usage

LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT® is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT® is also indicated for patients with exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.

Important Safety Information

  • LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose.

Important Safety Information

LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose.